r GWPH Stock Quote - GW Pharmaceuticals PLC Sponsored ADR Stock Price Today
TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds

GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
GWPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
0.44%165.230.4%$241.40m
VRXValeant Pharmaceuticals International, Inc.
0.07%22.2414.1%$211.47m
PRGOPerrigo Co. Plc
0.16%75.236.7%$103.69m
JAZZJazz Pharmaceuticals Plc
0.88%165.022.2%$91.57m
PTLAPortola Pharmaceuticals, Inc.
2.15%40.877.7%$78.12m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.71%161.107.6%$64.33m
SAGESAGE Therapeutics, Inc.
-1.80%155.339.6%$58.04m
MNKMallinckrodt Plc
0.37%16.5021.1%$57.03m
SUPNSupernus Pharmaceuticals, Inc.
2.88%57.256.3%$49.76m
PBHPrestige Brands Holdings, Inc.
2.21%34.653.8%$41.14m
UTHRUnited Therapeutics Corporation
-1.08%103.6014.4%$36.56m
HZNPHorizon Pharma plc
4.19%16.177.5%$33.22m
CTLTCatalent Inc
0.13%38.862.6%$31.43m
ICPTIntercept Pharmaceuticals, Inc.
1.88%71.0721.8%$30.30m
ENDPEndo International Plc
0.80%6.318.9%$29.81m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.